Expression and characterization of SARS-CoV-2 spike proteins

Jeffrey M. Schaub, Chia-Wei Chou, Hung-Che Kuo, Kamyab Javanmardi, Ching-Lin Hsieh, Jory Goldsmith, Andrea M. DiVenere, Kevin C. Le, Daniel Wrapp, Patrick O. Byrne, Christy K. Hjorth, Nicole V. Johnson, John Ludes-Meyers, Annalee W. Nguyen, Nianshuang Wang, Jason J. Lavinder, Gregory C. Ippolito, Jennifer A. Maynard, Jason S. McLellan, Ilya J. Finkelstein

Published: 2021-10-04 DOI: 10.1038/s41596-021-00623-0

SARS-CoV-2

purification

spike protein

HexaPro

expression

AI 解读

Fabrication of angstrom-scale two-dimensional channels for mass transport

Efficient and strand-specific profiling of replicating chromatin with enrichment and sequencing of protein-associated nascent DNA in mammalian cells

The eINTACT method for studying nuclear changes in host plant cells targeted by bacterial effectors in native infection contexts

Rapid reaction optimization by robust and economical quantitative benchtop19F NMR spectroscopy

Profiling native pulmonary basement membrane stiffness using atomic force microscopy

Photoimmunotechnology as a powerful biological tool for molecular-based elimination of target cells and microbes, including bacteria, fungi and viruses

Measuring key human carbohydrate digestive enzyme activities using high-performance anion-exchange chromatography with pulsed amperometric detection

Neural cell isolation from adult macaques for high-throughput analyses and neurosphere cultures

Preparation, validation and use of a vasoactive tryptophan-derived hydroperoxide and relevant control compounds

Neuronal subtype-specific growth cone and soma purification from mammalian CNS via fractionation and fluorescent sorting for subcellular analyses and spatial mapping of local transcriptomes and proteomes

查看全部

Sections

Figures

References

The severe acute respiratory syndrome coronavirus 2spike protein is a critical component of coronavirus disease 2019 vaccines and diagnostics and is also a therapeutic target. However, the spike protein is difficult to produce recombinantly because it is
Introduction
Materials
Procedure
Anticipated results
Troubleshooting
Timing
- Reporting Summary
- References
References
ACKNOWLEDGMENTS
ACKNOWLEDGMENTS

Ke, Z. et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature https://doi.org/10.1038/s41586-020-2665-2 (2020).
Turoňová, B. et al. In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. Science https://doi.org/10.1126/science.abd5223 (2020).
Chen, J., Gao, K., Wang, R., Nguyen, D. D. & Wei, G.-W. Review of COVID-19 antibody therapies. Annu. Rev. Biophys. https://doi.org/10.1146/annurev-biophys-062920-063711 (2020).
Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2027906 (2020).
Kim, D. et al. The architecture of SARS-CoV-2 transcriptome. Cell 181, 914–921.e10 (2020).
Finkel, Y. et al. The coding capacity of SARS-CoV-2. Nature https://doi.org/10.1038/s41586-020-2739-1 (2020).
Ullrich, S. & Nitsche, C. The SARS-CoV-2 main protease as drug target. Bioorg. Med. Chem. Lett. 30, 127377 (2020).
Buchholz, U. J. et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl Acad. Sci. USA 101, 9804–9809 (2004).
Gavor, E., Choong, Y. K., Er, S. Y., Sivaraman, H. & Sivaraman, J. Structural basis of SARS-CoV-2 and SARS-CoV antibody interactions. Trends Immunol. 41, 1006–1022 (2020).
Jeyanathan, M. et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 20, 615–632 (2020).
Klein, S. et al. SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography. Nat. Commun. 11, 5885 (2020).
Yao, H. et al. Molecular architecture of the SARS-CoV-2 virus. Cell 183, 730–738.e13 (2020).
Neuman, B. W. et al. A structural analysis of M protein in coronavirus assembly and morphology. J. Struct. Biol. 174, 11–22 (2011).
Hoffmann, M., Kleine-Weber, H. & Pöhlmann, S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell 78, 779–784.e5 (2020).
Coutard, B. et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antivir. Res. 176, 104742 (2020).
Wrobel, A. G. et al. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. Nat. Struct. Mol. Biol. 27, 763–767 (2020).
Papa, G. et al. Furin cleavage of SARS-CoV-2 spike promotes but is not essential for infection and cell-cell fusion. PloS Pathog. 17, e1009246 (2021).
Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 11727–11734 (2020).
Belouzard, S., Chu, V. C. & Whittaker, G. R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl Acad. Sci. USA 106, 5871–5876 (2009).
Cai, Y. et al. Distinct conformational states of SARS-CoV-2 spike protein. Science 369, 1586–1592 (2020).
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e6 (2020).
Henderson, R. et al. Controlling the SARS-CoV-2 spike glycoprotein conformation. Nat. Struct. Mol. Biol. 27, 925–933 (2020).
Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020).
Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444–1448 (2020).
Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327–330 (2020).
Zhou, T. et al. Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains. Cell Host Microbe 28, 867–879.e5 (2020).
Yi, C. et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol. Immunol. 17, 621–630 (2020).
Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224 (2020).
Huang, Y., Yang, C., Xu, X.-F., Xu, W. & Liu, S.-W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol. Sin. 41, 1141–1149 (2020).
Sternberg, A. & Naujokat, C. Structural features of coronavirus SARS-CoV-2 spike protein: targets for vaccination. Life Sci. 257, 118056 (2020).
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363–374 (2020).
Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. USA 114, E7348–E7357 (2017).
Kirchdoerfer, R. N. et al. Pre-fusion structure of a human coronavirus spike protein. Nature 531, 118–121 (2016).
Walls, A. C. et al. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531, 114–117 (2016).
Walls, A. C. et al. Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat. Struct. Mol. Biol. 23, 899–905 (2016).
Hsieh, C.-L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science https://doi.org/10.1126/science.abd0826 (2020).
Costello, S. M. et al. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. Preprint at bioRxiv https://doi.org/10.1101/2021.07.11.451855 (2021).
Huang, Y. et al. Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses. Preprint at bioRxiv https://doi.org/10.1101/2021.01.31.428824 (2021).
Javanmardi, K. et al. Rapid characterization of spike variants via mammalian cell surface display. Preprint at bioRxiv https://doi.org/10.1101/2021.03.30.437622 (2021).
Long, S. W. et al. Molecular architecture of early dissemination and massive second wave of the SARS-CoV-2 virus in a major metropolitan area. mBio 11, e02707-20 (2020).
Sun, Z. et al. Mass spectrometry analysis of newly emerging coronavirus HCoV-19 spike protein and human ACE2 reveals camouflaging glycans and unique post-translational modifications. Engineering (Beijing) https://doi.org/10.1016/j.eng.2020.07.014 (2020).
Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033–1036 (2020).
Crawford, K. H. D. et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. J. Infect. Dis. https://doi.org/10.1093/infdis/jiaa618 (2020).
Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956–963 (2020).
Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650–655 (2020).
Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450–456 (2020).
Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369, 731–736 (2020).
Zheng, Z. et al. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2. Euro Surveill. 25, 2000291 (2020).
Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295–1310.e20 (2020).
Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29, 44–57.e9 (2021).
Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2022483 (2020).
Keech, C. et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2026920 (2020).
Juraszek, J. et al. Stabilizing the closed SARS-CoV-2 spike trimer. Nat. Commun. 12, 244 (2021).
Bangaru, S. et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science https://doi.org/10.1126/science.abe1502 (2020).
McCallum, M., Walls, A. C., Bowen, J. E., Corti, D. & Veesler, D. Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. Nat. Struct. Mol. Biol. 27, 942–949 (2020).
Xiong, X. et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat. Struct. Mol. Biol. 27, 934–941 (2020).
Henderson, R. et al. Glycans on the SARS-CoV-2 spike control the receptor binding domain conformation. Preprint at bioRxiv https://doi.org/10.1101/2020.06.26.173765 (2020).
Gobeil, S. M.-C. et al. D614G mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1/S2 junction. Cell Rep. 34, 108630 (2021).
Jagtap, S. et al. Evaluation of spike protein antigens for SARS-CoV-2 serology. Preprint at medRxiv https://doi.org/10.1101/2021.01.27.21250382 (2021).
Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-CoV-2. Nat. Med. 26, 450–452 (2020).
Shajahan, A., Supekar, N. T., Gleinich, A. S. & Azadi, P. Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology 30, 981–988 (2020).
Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S. & Crispin, M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science https://doi.org/10.1126/science.abb9983 (2020).
Brun, J. et al. Analysis of SARS-CoV-2 spike glycosylation reveals shedding of a vaccine candidate. Preprint at bioRxiv https://doi.org/10.1101/2020.11.16.384594 (2020).
Johari, Y. B. et al. Production of trimeric SARS-CoV-2 spike protein by CHO cells for serological COVID-19 testing. Biotechnol. Bioeng. 118, 1013–1021 (2021).
Esposito, D. et al. Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays. Protein Expr. Purif. 174, 105686 (2020).
Asano, N. Glycosidase inhibitors: update and perspectives on practical use. Glycobiology 13, 93R–104R (2003).
Elbein, A. D., Tropea, J. E., Mitchell, M. & Kaushal, G. P. Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I. J. Biol. Chem. 265, 15599–15605 (1990).
Edwards, R. J. et al. Cold sensitivity of the SARS-CoV-2 spike ectodomain. Nat. Struct. Mol. Biol. https://doi.org/10.1038/s41594-020-00547-5 (2021).
Dzimianski, J. V. et al. Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry. Sci. Rep. 10, 21738 (2020).
Shah, N. B. & Duncan, T. M. Bio-layer interferometry for measuring kinetics of protein-protein interactions and allosteric ligand effects. J. Vis. Exp. https://doi.org/10.3791/51383 (2014).
Kumaraswamy, S. & Tobias, R. Label-free kinetic analysis of an antibody-antigen interaction using biolayer interferometry. Methods Mol. Biol. 1278, 165–182 (2015).
Olmedillas, E. et al. Structure-based design of a highly stable, covalently-linked SARS-CoV-2 spike trimer with improved structural properties and immunogenicity. Preprint at bioRxiv https://doi.org/10.1101/2021.05.06.441046 (2021).

Expression and characterization of SARS-CoV-2 spike proteins

Supplementary information

推荐阅读